PULSE-I - Is rePetitive Upper Limb SEnsory stimulation early after stroke feasible and acceptable? A stratified single-blinded randomised controlled feasibility study.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
01 Jul 2019
Historique:
received: 05 09 2018
accepted: 11 05 2019
entrez: 3 7 2019
pubmed: 3 7 2019
medline: 25 2 2020
Statut: epublish

Résumé

Reduction in sensorimotor function of the upper limb is a common and persistent impairment after stroke, and less than half of stroke survivors recover even basic function of the upper limb after a year. Previous work in stroke has shown that repetitive sensory stimulation (RSS) of the upper limb may benefit motor function. As yet, there have been no investigations of RSS in the early-acute period despite this being the time window during which the neuroplastic processes underpinning sensorimotor recovery are likely to occur. A single-blinded, stratified, randomised controlled feasibility study was undertaken at two NHS acute trusts to determine the recruitment rate, intervention adherence, and safety and acceptability of an RSS intervention in the early period after stroke. Participants were recruited within 2 weeks of index stroke. Stratified on arm function, they were randomised to receive either 45 min of daily RSS and usual care or usual care alone (UC) for 2 weeks. Changes from baseline on the primary outcome of the Action Research Arm Test (ARAT) to measurements taken by a blinded assessor were examined after completion of the intervention (2 weeks) and at 3 months from randomisation. Forty patients were recruited and randomised (RSS n = 23; UC n = 17) with a recruitment rate of 9.5% (40/417) of patients admitted with a stroke of which 52 (12.5%) were potentially eligible, with 10 declining to participate for various reasons. Participants found the RSS intervention acceptable and adherence was good. The intervention was safe and there were no serious adverse events. This study indicates that recruitment to a trial of RSS in the acute period after stroke is feasible. The intervention was well tolerated and appeared to provide additional benefit to usual care. In addition to a definitive trial of efficacy, further work is warranted to examine the effects of varying doses of RSS upon arm function and the mechanism by which RSS induces sensorimotor recovery in the acute period after stroke. ISRCTN, registry no: ISRCTN17422343 ; IRAS Project ID: 215137. Registered on October 2016.

Sections du résumé

BACKGROUND BACKGROUND
Reduction in sensorimotor function of the upper limb is a common and persistent impairment after stroke, and less than half of stroke survivors recover even basic function of the upper limb after a year. Previous work in stroke has shown that repetitive sensory stimulation (RSS) of the upper limb may benefit motor function. As yet, there have been no investigations of RSS in the early-acute period despite this being the time window during which the neuroplastic processes underpinning sensorimotor recovery are likely to occur.
METHODS METHODS
A single-blinded, stratified, randomised controlled feasibility study was undertaken at two NHS acute trusts to determine the recruitment rate, intervention adherence, and safety and acceptability of an RSS intervention in the early period after stroke. Participants were recruited within 2 weeks of index stroke. Stratified on arm function, they were randomised to receive either 45 min of daily RSS and usual care or usual care alone (UC) for 2 weeks. Changes from baseline on the primary outcome of the Action Research Arm Test (ARAT) to measurements taken by a blinded assessor were examined after completion of the intervention (2 weeks) and at 3 months from randomisation.
RESULTS RESULTS
Forty patients were recruited and randomised (RSS n = 23; UC n = 17) with a recruitment rate of 9.5% (40/417) of patients admitted with a stroke of which 52 (12.5%) were potentially eligible, with 10 declining to participate for various reasons. Participants found the RSS intervention acceptable and adherence was good. The intervention was safe and there were no serious adverse events.
CONCLUSIONS CONCLUSIONS
This study indicates that recruitment to a trial of RSS in the acute period after stroke is feasible. The intervention was well tolerated and appeared to provide additional benefit to usual care. In addition to a definitive trial of efficacy, further work is warranted to examine the effects of varying doses of RSS upon arm function and the mechanism by which RSS induces sensorimotor recovery in the acute period after stroke.
TRIAL REGISTRATION BACKGROUND
ISRCTN, registry no: ISRCTN17422343 ; IRAS Project ID: 215137. Registered on October 2016.

Identifiants

pubmed: 31262343
doi: 10.1186/s13063-019-3428-y
pii: 10.1186/s13063-019-3428-y
pmc: PMC6604268
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

388

Références

Neuroreport. 2002 Jul 19;13(10):1271-3
pubmed: 12151785
Stroke. 2003 Sep;34(9):2181-6
pubmed: 12907818
Health Technol Assess. 2010 May;14(26):1-113, iii-iv
pubmed: 20515600
Arch Neurol. 1989 Jun;46(6):660-2
pubmed: 2730378
Clin Rehabil. 2007 Feb;21(2):142-50
pubmed: 17264108
BMC Neurol. 2018 Jan 09;18(1):2
pubmed: 29316895
Neurorehabil Neural Repair. 2009 Jun;23(5):435-40
pubmed: 19261767
Clin Neurophysiol. 2012 Jan;123(1):193-9
pubmed: 21764634
Arch Phys Med Rehabil. 2008 Sep;89(9):1693-700
pubmed: 18760153
Neurorehabil Neural Repair. 2017 Jun;31(6):552-560
pubmed: 28506149
J Rehabil Res Dev. 2003 Jan-Feb;40(1):1-8
pubmed: 15150715
Clin Rehabil. 2002 Nov;16(7):709-16
pubmed: 12428819
Arch Phys Med Rehabil. 2015 Jun;96(6):981-90
pubmed: 25461822
Disabil Rehabil. 1999 Aug;21(8):357-64
pubmed: 10503976
Neurology. 2004 Jun 22;62(12):2262-9
pubmed: 15210892
Arch Phys Med Rehabil. 2012 Dec;93(12):2373-6.e5
pubmed: 22759831
Neurorehabil Neural Repair. 2010 Mar-Apr;24(3):263-72
pubmed: 19884642
Scott Med J. 1957 May;2(5):200-15
pubmed: 13432835
J Physiother. 2017 Jan;63(1):53
pubmed: 27964964
Disabil Rehabil. 2016;38(10):945-51
pubmed: 26200448
J Neurol Neurosurg Psychiatry. 2003 Dec;74 Suppl 4:iv18-iv21
pubmed: 14645462
Top Stroke Rehabil. 2011 Oct;18 Suppl 1:599-610
pubmed: 22120029
Neurorehabil Neural Repair. 2017 Sep;31(9):793-799
pubmed: 28934920
Neurorehabil Neural Repair. 2017 Sep;31(9):784-792
pubmed: 28934918
Cochrane Database Syst Rev. 2016 Nov 14;11:CD006073
pubmed: 27841442
Curr Biol. 2013 Jun 3;23(11):R489-99
pubmed: 23743417
Neurorehabil Neural Repair. 2012 Oct;26(8):923-31
pubmed: 22466792
Clin Rehabil. 2015 Dec;29(12):1234-43
pubmed: 25568073
Int J Rehabil Res. 1981;4(4):483-92
pubmed: 7333761
Disabil Rehabil. 2013 Feb;35(4):291-9
pubmed: 22691224
Lancet Neurol. 2006 Jul;5(7):603-12
pubmed: 16781990
Arch Phys Med Rehabil. 2009 Dec;90(12):2108-11
pubmed: 19969176
J Rehabil Med. 2001 Mar;33(3):110-3
pubmed: 11482350
Arch Phys Med Rehabil. 2006 Mar;87(3):351-7
pubmed: 16500168
Clinics (Sao Paulo). 2008 Dec;63(6):735-40
pubmed: 19060993
Eur Stroke J. 2018 Mar;3(1):82-91
pubmed: 29900412
Health Qual Life Outcomes. 2015 Aug 05;13:118
pubmed: 26243294
Arch Phys Med Rehabil. 2001 Jan;82(1):14-9
pubmed: 11239280
Ann Clin Transl Neurol. 2017 Oct 24;4(11):811-820
pubmed: 29159193
Lancet. 2014 Jan 18;383(9913):245-54
pubmed: 24449944
Neurorehabil Neural Repair. 2001;15(3):229-37
pubmed: 11944745
Am J Occup Ther. 1985 Jun;39(6):386-91
pubmed: 3160243
Neurosci Biobehav Rev. 2014 Nov;47:22-35
pubmed: 25064816
Brain. 2012 Aug;135(Pt 8):2527-35
pubmed: 22689909
Arch Phys Med Rehabil. 2007 Nov;88(11):1369-76
pubmed: 17964875

Auteurs

Kausik Chatterjee (K)

Countess of Chester Hospital Foundation Trust, Liverpool Rd, Chester, CH2 1UL, UK. kausikchatterjee@nhs.net.

Rachel C Stockley (RC)

Stroke Research Team, School of Nursing, University of Central Lancashire, Preston, PR1 2HE, UK.

Steven Lane (S)

Department of Biostatistics, University of Liverpool, Liverpool, L69 3GL, UK.

Caroline Watkins (C)

Stroke Research Team, School of Nursing, University of Central Lancashire, Preston, PR1 2HE, UK.

Katy Cottrell (K)

Countess of Chester Hospital Foundation Trust, Liverpool Rd, Chester, CH2 1UL, UK.

Brenda Ankers (B)

Countess of Chester Hospital Foundation Trust, Liverpool Rd, Chester, CH2 1UL, UK.

Sioned Davies (S)

Countess of Chester Hospital Foundation Trust, Liverpool Rd, Chester, CH2 1UL, UK.

Mary Fisher Morris (MF)

MemCheck Memory Clinic, Beehive Healthcare, Northgate Avenue, Chester, CH2 2DX, UK.

Nick Fallon (N)

Department of Psychological Sciences, University of Liverpool, Liverpool, L697ZA, UK.

Turo Nurmikko (T)

Neuroscience Research Centre, The Walton Centre NHS Foundation Trust, Liverpool, L9 7LJ, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH